Loading...
XNAS
PRTA
Market cap504mUSD
Jul 09, Last price  
9.64USD
1D
-2.13%
1Q
-8.19%
Jan 2017
-80.40%
IPO
41.76%
Name

Prothena Corporation PLC

Chart & Performance

D1W1MN
XNAS:PRTA chart
P/E
—
P/S
52.12
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.16%
Rev. gr., 5y
62.56%
Revenues
10m
-92.83%
1,243,000507,0002,658,000676,00050,854,0001,607,0001,055,00027,519,000955,000814,000853,000200,577,00053,905,00091,370,000135,157,0009,684,000
Net income
-244m
L+99.57%
-12,482,000-29,670,000-41,411,000-40,996,000-7,150,000-80,612,000-160,108,000-153,237,000-155,645,000-77,677,000-111,144,00066,975,000-116,949,000-147,028,000-122,310,000-244,092,000
CFO
-164m
L+9.02%
-9,083,000-19,697,000-42,072,000-32,098,000-683,000-62,455,000-117,269,000-131,183,000-28,276,000-52,969,000-80,362,00092,605,000-108,821,000-133,906,000-150,050,000-163,580,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
URL
https://www.prothena.com/
IPO date
Dec 21, 2012
Employees
127
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT